Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016
With Juno Therapeutics seriously delayed by a brief but painful clinical hold by the FDA, rival Kite Pharma outlined plans today to shoot for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.